R
Relay Therapeutics, Inc. (RLAY)
NGM – Real vaqt narxi. Valyuta: USD
12.93
+0.08 (0.62%)
Yopilishda: May 12, 2026, 4:00 PM EDT
13.13
+0.20 (1.56%)
Bozor oldidan: May 13, 2026, 5:50 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
12.93
+0.08 (0.62%)
Yopilishda: May 12, 2026, 4:00 PM EDT
13.13
+0.20 (1.56%)
Bozor oldidan: May 13, 2026, 5:50 AM EDT
Relay Therapeutics, Inc. klinik bosqichdagi aniq dori-darmonlar kompaniyasi sifatida faoliyat yuritadi. U onkologiya va genetik kasalliklar uchun kichik molekulalar terapiyasini kashf qilishga qaratilgan holda, dori-darmonlarni kashf qilish jarayonini o'zgartiradi. Kompaniyaning asosiy mahsulot nomzodlari orasida ko'krak bezi saratoni, qattiq o'smalar va tomirlar malformatsiyalarini davolash uchun klinik rivojlanishda bo'lgan pan-mutant va izoforma-selektiv fosfoinozitid 3 kinaza alfa, yoki PI3Kα inhibitori RLY-2608 hamda Fabry kasalliklari uchun αGal chaperoni mavjud. Shuningdek, u RAS signalizatsiya oqsillari oilasiga mansub onkogen drayveri RLY-8161ni ishlab chiqadi. Bundan tashqari, kompaniya saratonni davolash uchun retseptor tirozin kinazasi lirafugratinib (RLY-4008)ni ishlab chiqadi. U D. E. Shaw Research, LLC bilan D. E. Shaw Researchning oqsil harakatini tahlil qilishga qaratilgan hisoblash modellashtirish qobiliyatlaridan foydalangan holda ma'lum biologik nishonlarni tadqiq qilish, hamda ushbu nishonlarga yo'naltirilgan birikmalar va mahsulotlarni ishlab chiqish va tijoratlashtirish bo'yicha hamkorlik va litsenziya shartnomalariga ega; Elevar Therapeutics, Inc. bilan RLY-4008ni ishlab chiqish va tijoratlashtirish bo'yicha; va Pfizer Inc. bilan RLY-2608ni fulvestrant va atirmociclib bilan birgalikda ishlab chiqish bo'yicha shartnomalar tuzgan. Kompaniya avval Allostery, Inc. nomi bilan tanilgan va 2015-yil dekabr oyida Relay Therapeutics, Inc. nomini o'zgartirgan. Relay Therapeutics, Inc. 2015-yilda tashkil etilgan va Markaziy Massachusets shtatining Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Elliot Shaw Ph.D. | Founder |
| Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research & Development |
| Dr. Mark Murcko Ph.D. | Founder & Independent Director |
| Dr. Matthew P. Jacobson Ph.D. | Founder |
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, President & Director |
| Mr. Jim Watters Ph.D. | Chief Scientific Officer |
| Mr. Peter Rahmer | Chief Corporate Development Officer |
| Mr. Thomas Catinazzo | Chief Financial Officer |
| Ms. Dorothee Kern Ph.D. | Founder |
| Ms. Soo-Yeun Lim J.D. | Senior VP & General Counsel |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | rlay-20260505.htm |
| 2026-04-28 | DEFA14A | rlay_-_defa14a-naa_-_4.2.htm |
| 2026-04-27 | 8-K | rlay-20260427.htm |
| 2026-04-16 | PRE 14A | rlay-20260416.htm |
| 2026-03-16 | 8-K | rlay-20260316.htm |
| 2026-03-11 | 8-K | rlay-20260306.htm |
| 2026-02-26 | 8-K | rlay-20260226.htm |
| 2026-02-03 | 8-K | rlay-20260203.htm |
| 2025-11-06 | 8-K | rlay-20251104.htm |
| 2025-11-06 | 10-Q | rlay-20250930.htm |